LeMaitre Vascular SG&A Expenses 2010-2024 | LMAT

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

LeMaitre Vascular sg&a expenses from 2010 to 2024. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

LeMaitre Vascular sg&a expenses from 2010 to 2024. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.

Related Stocks
Company Name	Market Cap
Abbott Laboratories (ABT)	$202.2B
Stryker (SYK)	$143.3B
Boston Scientific (BSX)	$130.1B
Medtronic (MDT)	$112.5B
EssilorLuxottica (ESLOY)	$111.7B
Lonza Group Ag (LZAGY)	$45.4B
Haleon (HLN)	$43.5B
GE HealthCare Technologies (GEHC)	$39.3B
ResMed (RMD)	$37B
Terumo (TRUMY)	$29.6B
Koninklijke Philips (PHG)	$25B
Zimmer Biomet Holdings (ZBH)	$21.5B
Insulet (PODD)	$18.8B
Baxter (BAX)	$17.7B
Smith & Nephew SNATS (SNN)	$10.6B
Bio-Rad Laboratories (BIO)	$10.3B
BellRing Brands (BRBR)	$9.1B
Demant (WILYY)	$8.4B
Lantheus Holdings (LNTH)	$6.1B
Haemonetics (HAE)	$4.5B
TG Therapeutics (TGTX)	$4.5B
ICU Medical (ICUI)	$4.3B
Prestige Consumer Healthcare (PBH)	$4B
Perrigo (PRGO)	$3.6B
Neogen (NEOG)	$3.5B
Envista Holdings (NVST)	$3.5B
Agios Pharmaceuticals (AGIO)	$3.4B
GN Store Nord (GNNDY)	$3B
Shandong Weigao Medical Polymer (SHWGF)	$3B
QuidelOrtho (QDEL)	$2.9B